Latest Cordis Stories
Research reveals an aging population and increasing obesity rates fuel the €1.1 Billion dollar Endovascular devices market in Europe. (PRWEB) September 11,
Survey Reveals Most Cardiologists Would Use a Bioabsorbable Stent for Coronary Angioplasty According to iData Research Vancouver, BC (PRWEB) February 15, 2012
NEW BRUNSWICK, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that it expects to record an after-tax restructuring charge in the range of $500-$600 million in the second quarter of 2011 as a result of restructuring plans announced by its subsidiary, Cordis Corporation.
BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO(TM) Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists.
PARIS, May 16, 2011 /PRNewswire/ -- Cordis announces the launch in Europe of Radial Solutions, a complete portfolio for transradial interventions.
PARIS, May 16, 2011 /PRNewswire/ -- - Cordis Continues its History of Innovation With Two New Products: EMPIRA(TM) and RADIALSOURCE(TM) Cordis announced it has obtained CE mark for its EMPIRA(TM) and EMPIRA(TM) NC RX PTCA* Dilatation Catheters for the treatment of coronary artery disease.
MARSHALL, Texas, Jan. 28, 2011 /PRNewswire/ -- A federal jury in Marshall, Texas has returned a $482 million verdict for Dickstein Shapiro LLP client Dr. Bruce N. Saffran against defendants Johnson & Johnson and its subsidiary, Cordis Corporation, in Saffran v.
- The act of lurking; skulking about; hiding; keeping from sight.